Global Aplastic Anemia Market - 2022-2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	170 Pages	DataM Intelligence 4Market Research LLP	October, 2022	DTAM17463460

Best Price Guarantee
Price	from $4,350
Length	170 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	October, 2022
SKU	DTAM17463460

Global Aplastic Anemia Market - 2022-2029

Market Overview

Aplastic Anemia Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of YY% during the forecast period (2022-2029).

Aplastic anemia is a condition that happens when the body stops generating sufficient new blood cells. The condition leaves a person tired and more prone to uncontrolled bleeding and infections. Aplastic Anemia, a rare and serious condition, may develop at any age. It can happen suddenly or slowly and worsen over time. It can be either moderate or severe. Medications, blood transfusions or a stem cell transplant, also known as a bone marrow transplant, may be included in aplastic anemia treatment. The major factors propelling the growth of the aplastic anemia market are the rising number of blood disorder cases worldwide and the rising number of cancer patients globally. Moreover, the technological advancement in aplastic anemia and growing research & development activities in the pharmaceutical sector are further creating a lucrative opportunity for market growth.

Market Dynamics: Rising number of blood disorder cases worldwide drives the market growth

Aplastic anemia is a condition that happens when the body stops generating sufficient new blood cells. The condition leaves a person tired and more prone to uncontrolled bleeding and infections. Aplastic Anemia is a rare and serious condition of the body and may develop at any age. Aplastic anemia can happen suddenly or slowly and worsen over time. Aplastic Anemia can be either moderate or severe. Aplastic Anemia is cured by Medications, blood transfusions or a stem cell transplant, also known as a bone marrow transplant. The major factors propelling the growth of the aplastic anemia market are the rising number of blood disorder cases worldwide and the rising number of cancer patients globally. Moreover, the technological advancement in aplastic anemia and growing research & development activities in the pharmaceutical sector are further creating a lucrative opportunity for market growth.

Market Segmentation: The bone marrow transfusion/ stem cell therapy segment is projected to be the dominant segment in the market during the forecast period.

Based on the treatment type, the aplastic anemia market has been classified into bone marrow transfusion/stem cell therapy, blood transfusion and drug therapy.

For decades, hematopoietic stem cell transplantation has been used to treat blood and cardiovascular cell disorders, either unpatched or genetically altered to correct genetic disorders. Also, it is an efficient option for blood disorders with a success rate of over 80%, as per research presented by the American academy of orthopedic surgeons. Thus, rising blood disorders worldwide and efficient usage of stem cells in treating blood disorders are expected to drive the usage of bone marrow transfusion.

Aplastic anemia is segmented based on distribution channel, which includes retail pharmacies, hospitals pharmacies and online pharmacies.

Hospital pharmacies are held a significant market share in the aplastic anemia market. Hospital pharmacies held the dominant position in the global market during the forecast period. A hospital pharmacy is a specialized pharmacy integrated into the medical center's care. These include centers such as a hospital, outpatient clinics, drug-dependent facilities, poison control centers, and a drug information center at a residential care facility. The hospital's pharmacies are expected to gain potential growth in the forthcoming period due to the growing geriatric population and rising number of chronic diseases. Moreover, online pharmacies are expected to project a considerable CAGR during the forecast period. The rising e-commerce sector is expected to propel segment growth in the near future.

Additionally, aplastic anemia is segmented based on disease type, which includes acquired aplastic anemia and inherited bone marrow failure syndromes. Similarly, the route of administration includes intravenous and oral.

Geographical Penetration: North America region is expected to dominate the global aplastic anemia market

Based on geography, the study analyzes the aplastic anemia market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America is holding a dominant position in the global aplastic anemia market in 2021. The U.S. is expected to represent considerable growth in North America during the forecast period. In the U.S., aplastic anemia is expected to have potential growth owing to the high prevalence rate of blood disorders. Moreover, North America is expected to represent significant growth in terms of value during the forecast period. The rise in the prevalence rate of aplastic anemia and bone marrow disorder is expected to propel market growth across the region.

The aplastic anemia market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by the growth of the pharmaceutical industry & technological advancement in India and China. Moreover, the increasing population and increasing prevalence of chronic diseases are expected to augment the growth of the Asia Pacific aplastic anemia market.

Competitive Landscape:

The key aplastic anemia players which are contributing to the growth of the global market include Bayer AG, Novartis AG, Pfizer Inc., Ligand Pharmaceuticals Incorporated, Genezyme Corporation, Mylan N.V., BIOGEN, OTSUKA Pharmaceutical Co. Ltd., Regen Biopharma Inc., and BiolinRx, among others. The major players are adopting new product launches and expansion strategies for global growth in the aplastic anemia market. In August 2021, Pfizer acquired Global Blood Therapeutics for $5.4 Billion. This acquisition enhances the company’s presence in Rare Hematology. This acquisition expands the leading sickle cell disease expertise portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion. In October 2020, Ligand completed the acquisition of Pfenex Inc. for $437.5 million in cash, plus one non-transferable contingent value right (CVR) per share, representing the right to receive a contingent payment of $78 million in cash if a certain specified milestone is achieved. This acquisition provides a valuable technology platform and portfolio of royalty-bearing collaborations with leading pharmaceutical companies for treatments and vaccines. In June 2022, BioLineRx announced a collaboration agreement with GenFleet Therapeutics to develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC). This collaboration is based on positive final results from Phase 2a COMBAT/KEYNOTE-202 study of Motixafortide in combination with anti-PD-1 and chemotherapy as second-line metastatic PDAC therapy, which provides strong support for continued development in this very challenging disease.

COVID-19 Impact: Positive impact on the global aplastic anemia market.

The outbreak of COVID-19 has positively impacted the growth of the aplastic anemia market globally. Since people receive active treatment for aplastic anemia, immunosuppression involves a higher risk of infection and complications; however, it may be beneficial if immunosuppression reduces the late destruction of hyperinflammatory tissue. Therefore, the COVID-19 pandemic drove the market value of the aplastic anemia market in 2020.

The global aplastic anemia market report would provide an access to approximately 69 market data tables, 60 figures and 170 pages

1. Methodology and Scope: 1.1. Research Methodology; 1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary: 3.1. Market Snippet by Treatment Type; 3.2. Market Snippet by Disease Type; 3.3. Market Snippet by Route of Administration; 3.4. Market Snippet by Distribution Channel; 3.5. Market Snippet by Region
4. Market Dynamics: 4.1. Market Impacting Factors; 4.1.1. Drivers; 4.1.1.1. Rising number of blood disorder cases across the world; 4.1.1.2. Rising number of cancer patients; 4.1.2. Restraint; 4.1.2.1. High cost of treatment; 4.1.3. Impact Analysis
5. Industry Analysis: 5.1. Porter's Five Forces Analysis; 5.2. Supply Chain Analysis; 5.3. Value Chain Analysis; 5.4. PEST Analysis; 5.5. Pricing Analysis; 5.6. Regulatory Analysis; 5.7. Reimbursement Analysis; 5.8. Unmet Needs; 5.9. Patent Trends
6. COVID-19 Analysis: 6.1. Analysis of Covid-19 on the Market; 6.1.1. Before COVID-19 Market Scenario; 6.1.2. Present COVID-19 Market Scenario; 6.1.3. After COVID-19 or Future Scenario; 6.2. Pricing Dynamics Amid Covid-19; 6.3. Demand-Supply Spectrum; 6.4. Government Initiatives Related to the Market During Pandemic; 6.5. Manufacturers Strategic Initiatives; 6.6. Conclusion
7. By Treatment Type: 7.1. Introduction; 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment; 7.3. Market Attractiveness Index, By Treatment Type Segment; 7.3.1. Blood transfusion; 7.3.1.1. Introduction; 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%); 7.3.2. Drug therapy; 7.3.3. Bone Marrow Transfusion
8. By Diseases Type: 8.1. Introduction; 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment; 8.3. Market Attractiveness Index, By Diseases Type Segment; 8.3.1. Acquired aplastic anemia; 8.3.1.1. Introduction; 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%); 8.3.2. Inherited bone marrow failure syndromes
9. By Route of Administration: 9.1. Introduction; 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment; 9.3. Market Attractiveness Index, By Route of Administration Segment; 9.3.1. Intravenous; 9.3.1.1. Introduction; 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%); 9.3.2. Oral
10. By Distribution Channel: 10.1. Introduction; 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment; 10.3. Market Attractiveness Index, By Distribution Channel Segment; 10.3.1. Retail pharmacies; 10.3.1.1. Introduction; 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%); 10.3.2. Hospital pharmacies; 10.3.3. Online pharmacies
11. By Region: 11.1. Introduction; 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region; 11.3. Market Attractiveness Index, By Region; 11.4. North America; 11.4.1. Introduction; 11.4.2. Key Region-Specific Dynamics; 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type; 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel; 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type; 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration; 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country; 11.4.7.1. U.S.; 11.4.7.2. Canada; 11.4.7.3. Mexico; 11.5. Europe; 11.5.1. Introduction; 11.5.2. Key Region-Specific Dynamics; 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type; 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel; 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type; 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration; 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country; 11.5.7.1. Germany; 11.5.7.2. U.K.; 11.5.7.3. France; 11.5.7.4. Italy; 11.5.7.5. Spain; 11.5.7.6. Rest of Europe; 11.6. South America; 11.6.1. Introduction; 11.6.2. Key Region-Specific Dynamics; 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type; 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type; 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel; 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration; 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country; 11.6.7.1. Brazil; 11.6.7.2. Argentina; 11.6.7.3. Rest of South America; 11.7. Asia Pacific; 11.7.1. Introduction; 11.7.2. Key Region-Specific Dynamics; 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type; 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type; 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel; 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration; 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country; 11.7.7.1. China; 11.7.7.2. India; 11.7.7.3. Japan; 11.7.7.4. Australia; 11.7.7.5. Rest of Asia Pacific; 11.8. Middle East and Africa; 11.8.1. Introduction; 11.8.2. Key Region-Specific Dynamics; 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type; 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type; 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel; 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration; 11.8.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12. Competitive Landscape: 12.1. Competitive Scenario; 12.2. Market Positioning/Share Analysis; 12.3. Mergers and Acquisitions Analysis
13. Global Aplastic Anemia Market- Company Profiles: 13.1. Bayer AG*; 13.1.1. Company Overview; 13.1.2. Product Portfolio and Description; 13.1.3. Key Highlights; 13.1.4. Financial Overview; 13.2. Novartis AG; 13.3. Pfizer Inc.; 13.4. Ligand Pharmceuticals Incorporated; 13.5. Genezyme Corporation; 13.6. Mylan N.V.; 13.7. BIOGEN; 13.8. Otsuka Pharmaceutical Co. Ltd.; 13.9. REGEN BIOPHARMA INC.; 13.10. BiolinRx (*LIST NOT EXHAUSTIVE)
14. Premium Insights
15. DataM Intelligence Analysis: 15.1. Appendix; 15.2. About Us and Services; 15.3. Contact Us